{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:14:16Z","timestamp":1791267256086,"version":"4.1.0"},"reference-count":50,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2004,12,7]],"date-time":"2004-12-07T00:00:00Z","timestamp":1102377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Internal Medicine"],"published-print":{"date-parts":[[2005,1]]},"abstract":"<jats:title>Abstract.<\/jats:title><jats:p><jats:bold>Objectives.\u2002<\/jats:bold> The UK Prospective Diabetes Study (UKPDS) showed that treatment with metformin decreases macrovascular morbidity and mortality independent of glycaemic control. We hypothesized that metformin may achieve this by improving endothelial function and chronic, low\u2010grade inflammation. Data on this issue are scarce and we therefore tested, in the setting of a randomized, placebo\u2010controlled trial, whether metformin can affect endothelial function and low\u2010grade inflammation.<\/jats:p><jats:p><jats:bold>Design.\u2002<\/jats:bold> The Hyperinsulinaemia the Outcome of its Metabolic Effects (HOME) trial is a double\u2010blind trial, in which all patients were randomized to receive either metformin or placebo in addition to insulin therapy. At the beginning and the end of a 16\u2010week treatment period fasting blood samples were drawn and a physical examination was carried out.<\/jats:p><jats:p><jats:bold>Setting.\u2002<\/jats:bold> The trial was conducted in the outpatient clinics of three nonacademic hospitals (Hoogeveen, Meppel and Coevorden; the Netherlands).<\/jats:p><jats:p><jats:bold>Subjects.\u2002<\/jats:bold> Patients were included if they were between 30 and 80\u2003years of age; had received a diagnosis of diabetes after the age of 25; had never had an episode of ketoacidosis; and their blood glucose\u2010lowering treatment previously consisted of oral agents but now only consisted of either insulin (<jats:italic>n<\/jats:italic>\u2003=\u2003345) or insulin and metformin (<jats:italic>n<\/jats:italic>\u2003=\u200345). We excluded pregnant women and women trying to become pregnant, patients with a Cockroft\u2010Gault\u2010estimated creatinine clearance &lt;50\u2003mL\u2003min<jats:sup>\u22121<\/jats:sup>, or low plasma cholinesterase (reference value &lt;3.5\u2003units\u2003L<jats:sup>\u22121<\/jats:sup>), patients with congestive heart failure (New York Heart Association class III\/IV), or patients with other serious medical or psychiatric disease. A total of 745 eligible patients were approached; 390 gave informed consent and were randomized (196 metformin, 194 placebo). About 353 patients completed 16\u2003weeks of treatment (171 metformin, 182 placebo).<\/jats:p><jats:p><jats:bold>Main outcome measures.\u2002<\/jats:bold> The HOME trial was designed to study the metabolic and cardiovascular effects of metformin during a follow\u2010up of 4\u2003years. Presented here are the results of an interim analysis after 16\u2003weeks of treatment.<\/jats:p><jats:p><jats:bold>Results.\u2002<\/jats:bold> When compared with placebo, metformin treatment was associated with an increase in urinary albumin excretion of 21% (\u22121 to +48; <jats:italic>P<\/jats:italic>\u2003=\u20030.06); a decrease in plasma von Willebrand factor of 6% (\u221210 to \u22122; <jats:italic>P<\/jats:italic>\u2003=\u20030.0007); a decrease in soluble vascular cell adhesion molecule\u20101 of 4% (\u22127 to \u22122; <jats:italic>P<\/jats:italic>\u2003=\u20030.0002); a decrease in soluble E\u2010selectin of 6% (\u221210 to \u22122; <jats:italic>P<\/jats:italic>\u2003=\u20030.008); a decrease in tissue\u2010type plasminogen activator of 16% (\u221220 to \u221212; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001); and a decrease in plasminogen activator inhibitor\u20101 of 20% (\u221227 to \u221210; <jats:italic>P<\/jats:italic>\u2003= 0.0001). These changes could not be explained by metformin\u2010associated changes in glycaemic control, body weight or insulin dose. Markers of inflammation, i.e. C\u2010reactive protein and soluble intercellular adhesion molecule\u20101, did not change with metformin treatment.<\/jats:p><jats:p><jats:bold>Conclusions.\u2002<\/jats:bold> In patients with type 2 diabetes treated with insulin, metformin treatment was associated with improvement of endothelial function, which was largely unrelated to changes in glycaemic control, but not with improvement of chronic, low\u2010grade inflammation.<\/jats:p>","DOI":"10.1111\/j.1365-2796.2004.01420.x","type":"journal-article","created":{"date-parts":[[2004,12,7]],"date-time":"2004-12-07T15:01:52Z","timestamp":1102431712000},"page":"100-109","source":"Crossref","is-referenced-by-count":167,"title":["Effects of short\u2010term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo\u2010controlled trial"],"prefix":"10.1111","volume":"257","author":[{"given":"J.","family":"DE JAGER","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"KOOY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ph.","family":"LEHERT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"BETS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. G.","family":"WULFFEL\u00c9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"TEERLINK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. G.","family":"SCHEFFER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. G.","family":"SCHALKWIJK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J. M.","family":"DONKER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. D. A.","family":"STEHOUWER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,12,7]]},"reference":[{"key":"e_1_2_16_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"e_1_2_16_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901143400207"},{"key":"e_1_2_16_4_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.4.1157"},{"key":"e_1_2_16_5_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.49.3.485"},{"key":"e_1_2_16_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01129-9"},{"key":"e_1_2_16_7_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.16.4.621"},{"key":"e_1_2_16_8_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.11.1967"},{"key":"e_1_2_16_9_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.19.1.64"},{"key":"e_1_2_16_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.1999.00497.x"},{"key":"e_1_2_16_11_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.12.2133"},{"key":"e_1_2_16_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_16_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(95)06067-N"},{"key":"e_1_2_16_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2003.01213.x"},{"key":"e_1_2_16_15_2","first-page":"709","article-title":"A new biometrical procedure for testing the equality of measurements from two different analytical methods: I. Application of linear regression procedures for method comparison studies in clinical chemistry","volume":"21","author":"Passing H","year":"1983","journal-title":"J Clin Chem Clin Biochem"},{"key":"e_1_2_16_16_2","first-page":"431","article-title":"Comparison of several regression procedures for method comparison studies and determination of sample sizes: II. Application of linear regression procedures for method comparison studies in clinical chemistry","volume":"22","author":"Passing H","year":"1984","journal-title":"J Clin Chem Clin Biochem"},{"key":"e_1_2_16_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/43.10.1904"},{"key":"e_1_2_16_18_2","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1093\/clinchem\/44.10.2148","article-title":"Measurement of LDL particle size in whole plasma and serum by high performance gel\u2010filtration chromatography using a fluorescent lipid probe","volume":"44","author":"Scheffer PG","year":"1998","journal-title":"Clin Chem"},{"key":"e_1_2_16_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(96)00272-6"},{"key":"e_1_2_16_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.18.9.1359"},{"key":"e_1_2_16_21_2","first-page":"1075","article-title":"Clinically important factors influencing endothelial function","volume":"7","author":"Vapaatalo H","year":"2001","journal-title":"Med Sci Monit"},{"key":"e_1_2_16_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/hh2101.099270"},{"key":"e_1_2_16_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200003233421202"},{"key":"e_1_2_16_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.1991.tb01610.x"},{"key":"e_1_2_16_25_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.12.2123"},{"key":"e_1_2_16_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.1999.00201.x"},{"key":"e_1_2_16_27_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.6.1008"},{"key":"e_1_2_16_28_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.3.549"},{"key":"e_1_2_16_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.18.5.723"},{"key":"e_1_2_16_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/hc4401.098490"},{"key":"e_1_2_16_31_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615401"},{"key":"e_1_2_16_32_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.12.2135"},{"key":"e_1_2_16_33_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-5-199903020-00002"},{"key":"e_1_2_16_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0188-4409(00)00241-1"},{"key":"e_1_2_16_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00285287"},{"key":"e_1_2_16_36_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021688"},{"key":"e_1_2_16_37_2","doi-asserted-by":"publisher","DOI":"10.1089\/15209150050025230"},{"key":"e_1_2_16_38_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-1-200207020-00009"},{"key":"e_1_2_16_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1262-3636(03)72796-7"},{"key":"e_1_2_16_40_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.48.1.198"},{"key":"e_1_2_16_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(99)00263-4"},{"key":"e_1_2_16_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00342-8"},{"key":"e_1_2_16_43_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.12.1863"},{"key":"e_1_2_16_44_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.74.5.1020"},{"key":"e_1_2_16_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(02)02464-6"},{"key":"e_1_2_16_46_2","doi-asserted-by":"publisher","DOI":"10.1053\/meta.2002.31332"},{"key":"e_1_2_16_47_2","doi-asserted-by":"publisher","DOI":"10.1053\/meta.2001.28078"},{"key":"e_1_2_16_48_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.52.3.667"},{"key":"e_1_2_16_49_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021193"},{"key":"e_1_2_16_50_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-978682"},{"key":"e_1_2_16_51_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-979059"}],"container-title":["Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2796.2004.01420.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2796.2004.01420.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T17:18:23Z","timestamp":1697131103000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2796.2004.01420.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12,7]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["10.1111\/j.1365-2796.2004.01420.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2796.2004.01420.x","archive":["Portico"],"relation":{},"ISSN":["0954-6820","1365-2796"],"issn-type":[{"value":"0954-6820","type":"print"},{"value":"1365-2796","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12,7]]}}}